Episodic Migraine Clinical Trial
Official title:
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Evidence-based medicine depends on distinguishing between pharmacological effects and
placebo effects in randomized controlled trials (RCT). This proposal seeks to rigorously
investigate fundamental questions concerning pharmacological effects, placebo effects and
their interactions. Relief of symptoms of acute migraine will be the test condition for this
scientific experiment because of migraine's evident clinical significance and the
possibility of using participants as their own control during sequential acute migraine
attacks. Our overall goal is to elucidate how the pharmacological effects of 100 mg
rizatriptan (an FDA-proven effective medication for acute migraine) and the effects of
placebo treatment can be modified by varied knowledge and/or expectation ("contextual")
conditions. Such knowledge has the possibility to suggest potentially more efficient
methodologies to test new medications that can be used to augment and enhance the apparatus
of the RCT.
General Aim: To elucidate and clarify what is a pharmacological effect and what is a placebo
effect, how such effects vary in different knowledge/expectations contexts, and mutually
constitute one another and interact.
General Hypothesis: The measured pharmacological effect of an effective medication
(rizatriptan) and the measured effect of placebo treatment are determined significantly by
different knowledge/expectations contexts.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
| Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
| Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
| Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
| Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
| Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
| Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
| Active, not recruiting |
NCT05028569 -
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
|
Phase 3 | |
| Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
| Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
| Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
| Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
| Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
| Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
| Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
| Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
| Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
| Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 | |
| Active, not recruiting |
NCT05853900 -
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
|
Phase 3 |